

Phase separation-mediated condensation of N protein-deaminase complex promotes SARS-CoV-2 mutagenesis

Xingxu Huang (✉ huangxx@shanghaitech.edu.cn)

Zhejiang University School of Medicine <https://orcid.org/0000-0001-8934-1247>

Zhean Li

Zhejiang University School of Medicine

Lingling Luo

ShanghaiTech University

Xiaohui Ju

Tsinghua University

Shisheng Huang

ShanghaiTech University

Jia Liu

ShanghaiTech University <https://orcid.org/0000-0001-9787-465X>

Pumin Zhang

Zhejiang University School of Medicine

Tian Chi

ShanghaiTech University

Peixiang Ma

Shanghai Jiao Tong University School of Medicine

Cheng Huang

Shanghai University of Traditional Chinese Medicine

Qiang Ding

Tsinghua University

Yu Zhang

ShanghaiTech University

Article

Keywords: SARS-CoV-2, Nucleocapsid protein, RNA-protein condensates, Mutagenesis, Deaminases

Posted Date: April 27th, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1566705/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

31 **Abstract**

32 The emergence of SARS-CoV-2 variants poses enormous challenges to the prevention
33 and control of COVID-19 with alterations in antigenicity, transmissibility and
34 pathogenicity. The rapid evolution of RNA viruses could be caused by high mutation
35 frequencies during replication, arising by replication errors, intergenomic
36 recombination or even host deaminases. We sought to understand whether host
37 deaminases are involved in SARS-CoV-2 mutation, and how they orchestrate host
38 deaminases to trigger this process. Herein, we provided the experimental evidence that
39 APOBEC and ADAR deaminases act as the driving forces for SARS-CoV-2
40 mutagenesis. Mechanistically, SARS-CoV-2 nucleocapsid (N) protein, which is
41 responsible for packaging viral genomic RNA, complexes with host deaminases to
42 facilitate viral RNA mutation. Moreover, N protein employs deaminases-involved
43 condensates to further promote viral RNA mutation. Mutant N protein with F17A
44 substitution, defective in entry of deaminases-involved RNA granules, leads to the
45 decreased mutation of viral RNA, confirming the function of N protein-deaminase
46 condensates on RNA editing. Our study sheds light on the novel mechanism of SARS-
47 CoV-2 mutation during host-virus arms race.

48

49 **Keywords:** SARS-CoV-2, Nucleocapsid protein, RNA-protein condensates,
50 Mutagenesis, Deaminases

51

52

53

54

55

56

57

58

59

60

61 **Introduction**

62 The continuous emergence of SARS-CoV-2 variants of concerns (VOC) with
63 alterations in transmissibility, antigenicity and pathogenicity in human has posed an
64 ongoing threat to global health¹⁻⁴. Currently, the World Health Organization (WHO) has
65 defined five variants as VOC, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta
66 (B.1.617.2) and Omicron (B.1.1.529), as well as two further variants of interest (VOI),
67 Lambda (C.37) and Mu (B.1.621) and a new recombinant variant, XE^{5, 6}. The VOCs
68 and VOIs have exhibited abilities to evade neutralization by monoclonal antibodies or
69 vaccine induced immunity, which presents urgent challenges for curbing COVID-19^{2,}
70 ⁷⁻¹⁰.

71 SARS-CoV-2, belonging to subfamily Coronavirinae in the family Coronaviridae of the
72 order Nidovirales, is a positive-sense, single-strand (ss) RNA virus and possesses a
73 moderate genetic variability due to their RNA-proofreading machinery which utilizes
74 nsp14 exonuclease to correct errors^{11, 12}. In general, viral RNA mutations are emerged
75 from two main sources which contain spontaneous random errors in replication made
76 by RNA dependent RNA polymerase (RdRP) that are not corrected by the existing
77 proofreading mechanism, and host-driven viral genome mutation, such as deaminase-
78 mediated RNA editing and reactive oxygen species (ROS)¹³⁻¹⁵.

79 The human deaminases, which consist of the adenosine deaminases acting on RNA
80 (ADARs) and the apolipoprotein-B (*ApoB*) mRNA editing enzyme, catalytic
81 polypeptide-like proteins (APOBECs)¹⁶, play a critical role in the innate antiviral
82 defense. The ADARs are able to deaminate adenosine in dsRNAs and convert it into
83 inosine (A-to-I). Three types of ADAR genes (ADAR1, ADAR2 and ADAR3) have
84 been identified in human genome. ADAR1 and ADAR2 are expressed in almost all
85 human tissues and catalytically active for adenosine deamination, while ADAR3 is
86 absent outside of the brain and has no reported deamination activity^{17, 18}. ADAR1/2
87 possess antiviral effects by destabilizing dsRNA through introducing multiple A-to-I
88 (G) substitutions, which were described for several RNA viruses, including influenza
89 virus, lymphocytic choriomeningitis virus, rift valley fever virus, hepatitis C virus and

90 Zika virus^{19, 20}. The APOBECs are a family of cytosine deaminases, which catalyze
91 cytosine deamination to uracil (C-to-U) in single-stranded DNA or RNA. The
92 APOBECs family contains eleven APOBEC members: APOBEC1, APOBEC2,
93 APOBEC3 (A, B, C, D, F, G and H), APOBEC4 and activation-induced cytidine
94 deaminase (AID)²¹. Similar to the ADARs, APOBEC proteins restrict viral replication
95 due to their feature of hyper-editing, such as HIV and HBV²². APOBEC1, APOBEC3A
96 and APOBEC3G are also reported to recognize and deaminate ssRNA to cause C-to-U
97 mutation²³⁻²⁶. The ROS, also as an antiviral strategy, could oxidize nucleic acids to
98 induce virus inactivation and mutagenesis, which is proposed to be related to the G-to
99 U and C-to-A transversions^{27, 28}. In the host-virus interaction, the host cells utilize the
100 innate antiviral response to induce virus mutagenesis and inactivation, and thereby
101 combat virus infection. On the contrary, the viruses develop multiple mechanisms to
102 employ host-driven forces to achieve viral mutagenesis and evolution, and thereby
103 enhances virus adaption and fitness.

104 The analysis of existing SARS-CoV-2 mutations and SARS-CoV-2 RNA-seq data from
105 COVID-19 patients displayed predominant mutational patterns with specific signatures
106 of A-to-I (G) and C-to-U (T) mutation, indicating that ADARs and APOBECs-mediated
107 RNA editing likely plays a crucial role in SARS-CoV-2 mutagenesis^{13, 14}. However,
108 whether host deaminases are involved in SARS-CoV-2 mutation and how SARS-CoV-
109 2 hijacks host deaminases to achieve viral mutation and evolution are still unknown. In
110 our study, we provided the experimental evidence that host deaminases, ADARs and
111 APOBECs, indeed act as the driving forces for RNA mutation of SARS-CoV-2. The
112 potential mechanism is that host deaminases specifically interacted with N protein (a
113 viral RNA binding protein in viral life cycle), which may link deaminases to target viral
114 RNA for editing. Furthermore, N protein partitions into deaminases-involved RNA
115 granule via phase separation, which concentrates RNA and proteins to enhance
116 deaminases interaction with N protein and viral RNA, and thereby promotes RNA
117 editing efficiency. Furthermore, N^{F17A} protein loses the capability to entry into stress
118 granules (SGs), which impairs the interaction level with deaminase and decreases the

119 SARS-CoV-2 RNA mutagenesis, further supporting the function of deaminases-
120 involved condensates on RNA editing. Our study may shed light on a novel therapeutic
121 strategy against SARS-CoV-2 variants.

122 **Results**

123 **N protein interacts with host deaminases and then guides host deaminases to edit** 124 **viral RNA**

125 The predominant mutational patterns in SARS-CoV-2 genome with the signatures of
126 A-to-I (G) and C-to-U (T) mutation implies that APOBEC and ADAR-mediated RNA
127 editing may contribute to shape the viral RNA mutational outcome and promote SARS-
128 CoV-2 evolution^{13, 16}. To confirm the role of the deaminases in viral mutation, we
129 utilized an N protein-based trans-complementation SARS-CoV-2 cell culture model in
130 Caco-2 cells²⁹, and performed RNA-seq to analyze mutational patterns of SARS-CoV-
131 2 genome. With the reference sequence of SARS-CoV-2 genome (NC_045512), we
132 analyzed the proportion of 12 single nucleotides variant (SNV) types based on four
133 nucleotides (A: A>C, A>G, A>T; C: C>A, C>G, C>T; G: G>A, G>C, G>T; T: T>A,
134 T>C, T>G). Consistent with the reported mutational pattern^{13, 14}, APOBEC-mediated
135 C-to-U (C>T/G>A) and ADAR-mediated A-to-I (A>G/T>C) account for the
136 predominant proportion in mutational ratio (Fig. 1a; Supplementary Fig. S1a),
137 suggesting that the deaminase-induced RNA editing potentially occurred in SARS-
138 CoV-2 RNA genome. However, SARS-CoV-2 infection did not alter the mRNA
139 expression of APOBECs and ADARs (Supplementary Fig. S1b), suggesting that viral
140 mutation is not induced by the change of deaminase level. The G-to-U (G>T) and C-
141 to-A (C>A) transversions are the second main group for nucleotides C and G mutation
142 (Fig. 1a; Supplementary Fig. S1a), which was likely contributed by reactive oxygen
143 species (ROS) activity²⁷. Since APOBECs or ADARs-catalyzed deamination of C-to-
144 U or A-to-U is regulated by specific sequence contexts, we performed the analysis of
145 the nucleotide contexts in the SARS-CoV-2 genome. We observed that the AA and GA
146 are the most and the least preferable motifs for A-to-I mutation on the SARS-CoV-2
147 genome, respectively (Fig. 1b), which is similar to the context preference of hADARs³⁰,

148 ³¹. On the other hand, C-to-U transitions on the SARS-CoV-2 genome preferentially
149 occur at the downstream of adenosines or uridines, and the upstream of adenosines or
150 uridines (Fig. 1b), which are in line with the reported motif preference for RNA editing
151 by APOBECs^{24,32}. Notably, each nucleotides variant is evenly represented with respect
152 to SNV frequency suggesting the strength of driving forces to induce SARS-CoV-2
153 mutation presents less difference (Fig. 1c).

154 To gain further insight into the role of host deaminase in SARS-CoV-2 mutation, we
155 performed a series of virus passages on Caco-2 cells and collected the SARS-CoV-2
156 RNA after one and six passages to perform RNA-sequencing. At the first passage, the
157 extensive C-to-U and A-to-I substitutions were displayed by the SARS-CoV-2 genome
158 suggested that host deaminases induced viral genome hypermutation, the purpose of
159 which is to mutate the viral RNA, and then restrict the viral RNA replication in the early
160 stages of SARS-CoV-2 infection (Fig. 1d). Strikingly, the count of SNVs number
161 dramatically decreased at the sixth passage of SARS-CoV-2 (Fig. 1d). One possible
162 reason is that most of the mutations lead to the deficiency of viral RNA replication, and
163 only mutations, i.e. T2578C, C5219T, A19736G and C27970T, which do not impair
164 viral fitness could be maintained in the following passages (Supplementary Fig. S1c),
165 further supporting that host deaminase indeed function as host restriction factors to
166 induce viral genome hypermutation and inactivation upon SARS-CoV-2 infection.
167 Conversely, the viruses could employ cellular deaminase to edit SARS-CoV-2 viral
168 genome and achieve viral evolution, and thereby enhance virus fitness.

169 The function of host deaminases in driving SARS-CoV-2 viral genome mutations have
170 been well characterized, but it is not yet known how SARS-CoV-2 virus hijacks host
171 deaminases to deaminate viral RNA in the viral life cycle. SARS-CoV-2 nucleocapsid
172 (N) protein, which is responsible for assembling viral RNA genome to form
173 ribonucleoprotein (RNP) complex could interact host RNA-binding proteins and
174 regulated SG formation to overcome host antiviral response^{33, 34}. The deaminases
175 (ADARs and APOBECs) also function as host RNA-binding proteins and favor RNA
176 to occur deamination^{17, 23}. In light of their function, we hypothesize that N protein act

177 as a host-virus intermediary to direct host-encoded cytidine/adenine deaminases to edit
178 the viral RNA. To test this hypothesis, we first investigated whether N protein interacted
179 with host deaminases. We systematically co-expressed GFP-tagged N protein and flag-
180 tagged APOBEC family members (APOBEC1, activation-induced cytidine deaminase
181 (AID), APOBEC2, APOBEC3 (A to F), and APOBEC4) or ADAR family members
182 (ADAR1 and ADAR2) in HeLa cells, and then performed Co-IP experiment to detect
183 the interaction of GFP-tagged N protein with each host deaminase. The results showed
184 that N protein interacted with ADARs (ADAR1 and ADAR2) and some members of
185 APOBECs, such as APOBEC1, AID, APOBEC3D, APOBEC3F, APOBEC3G and
186 APOBEC3H, but not APOBEC2, APOBEC3A, APOBEC3C and APOBEC4 (Fig. 1e).
187 Meanwhile, we transfected N gene in HeLa cells and then performed RNA
188 immunoprecipitation (RIP) assay using anti-ADAR2 antibody to detect the interaction
189 between ADAR2 and viral RNA. The result showed that ADAR2 bound the RNA of N
190 protein, suggesting N protein directly bridges the host deaminases with viral RNA (Fig.
191 1f). Next, we validated whether host deaminases could induce mutations on the RNA
192 which encodes viral proteins. We transfected viral N gene into HeLa cells and
193 performed RNA-seq to analyze mutational signature of N gene RNA. Similar to
194 mutational pattern of SARS-CoV-2 genome, the mutation bias toward transitions,
195 including A>G/T>C and C>T/G>A, further confirming the host deaminase function
196 (Fig. 1g). Moreover, AAG and GCA are the most preferable motifs for A-to-I mutation
197 and C-to-U mutation, respectively (Supplementary Fig. S2a), which are consistent with
198 the sequence context of N gene in the SARS-CoV-2 genome (Supplementary Fig. S2b).
199 The similar results were observed on the RNA of spike gene in HeLa cells when spike
200 gene and N gene were co-transfected into HeLa cells (Supplementary Fig. S2c). The
201 SARS-CoV-2 genome encodes some non-structural proteins (nsp) to assist the viral
202 RNA processing and replication, including nsp7, nsp8, nsp9, nsp12 and nsp16. To check
203 the possibility of other viral factors interaction with host deaminases, we chose the
204 aforementioned nsp and four structural proteins (S, N, E, M) to perform Co-IP assay
205 with host deaminases. The results showed that APOBEC3G (A3G) or ADAR2 failed to
206 interact with those nsp and structural proteins. However, N protein showed a strong

207 interaction with A3G or ADAR2 (Fig. 1h; Supplementary Fig. S2d). Thus, specific
208 interaction between N protein with host deaminases is a potential mechanism for host-
209 directed RNA editing of the SARS-CoV-2 genome.

210 **The condensate formation of N-deaminase complex efficiently enhances the viral** 211 **RNA mutagenesis**

212 Our previously study have reported that N protein interacted with host RNA-binding
213 proteins G3BP (the core proteins in SGs)³³, which provoked us to explore whether N
214 protein interacts with G3BP and host deaminases to form multi-proteins complex. To
215 this end, we co-expressed GFP-tagged N protein and HA-tagged A3G or ADAR2 in
216 HeLa cells and then the cell lysate was immunoprecipitated by the antibody against
217 GFP, followed by the detection of endogenous G3BP1 and A3G or ADAR2 using the
218 antibody against G3BP1 and HA. N protein is able to interact with host G3BP1 and
219 A3G or ADAR2 (Fig. 2a), suggesting that G3BP1 and host deaminases act as host
220 binding partners of viral N protein and may be jointly involved in stress granules (SGs).
221 SGs are the membrane-less dynamic structures containing large cytoplasmic mRNA-
222 protein aggregates^{35, 36}. Viral infection induces host SG formation which functions as a
223 barrier to insulate the virus via inhibiting translation of viral mRNA³⁷⁻⁴⁰. SARS-CoV-2
224 RNA is able to induce SG formation⁴¹, and the N protein co-localized in SGs³³. We thus
225 verified whether host deaminases co-localized with N protein in SGs. The cells were
226 transfected with the plasmids encoding mCherry-tagged N protein and BFP-tagged
227 deaminases AID, A3G, APOBEC3H or ADAR2, and then immunostained by antibodies
228 against endogenous G3BP1 (SG marker). Under the stress condition, N protein
229 specifically co-localized with G3BP1 and AID, APOBEC3G, APOBEC3H or ADAR2
230 in SGs, instead of other SARS-CoV-2 related proteins (Fig. 2b; Supplementary Fig.
231 S3a-S3c). ADAR2 and APOBEC3H mainly localized to the nucleus in the resting
232 conditions, however, they partially translocated to the cytoplasm and localized with N
233 protein in SGs under the stress condition (Fig. 2b; Supplementary Fig. S3b). SGs, one
234 type of RNA granule which is formed by phase separation, is able to concentrate RNA
235 and RNA-binding proteins into condensed compartments^{42, 43}. To examine whether

236 such compact organization can promote the interaction between deaminases and N
237 protein or RNA. We transfected cDNA encoding N protein in HeLa cells and performed
238 Co-IP and RIP assay. As our expected, when N protein were recruited into SGs, the
239 formation of RNA-protein condensates enhanced the interaction level between host
240 deaminase and N protein or RNA (Fig. 2c and 2d). Phase-separated condensates is able
241 to accelerate their related reaction by concentrating molecular⁴⁴. Thus, we next
242 investigated whether the condensed RNA-deaminases interactions could boost the
243 RNA-editing activity of host deaminases. For this purpose, we co-expressed N, spike
244 or Orf 8 in HeLa cells and then treated cells with stress stimulator to induce SG
245 formation. APOBEC-regulated C-to-U (C>T/G>A) and ADAR-mediated A-to-I
246 (A>G/T>C) mutations still accounted for the predominant proration of mutational
247 signature under stress condition (Supplementary Fig. S4), suggesting SG formation is
248 unable to change deaminases function. Interestingly, the formation of N protein-
249 deaminases condensates remarkably increased the number of SNVs in the transcripts
250 of N, spike and Orf 8 (Fig. 2e-2g). Moreover, the frequency of SNVs was greatly
251 upregulated (Fig. 2h and 2i), suggesting the condensation enhanced the RNA-
252 deaminases interaction, and thereby promoted RNA mutagenesis. Surprisingly, the
253 frequency of two VOC (variant of concern) mutants, A23403G (D614G in spike protein)
254 and C27972T (Q27* in Orf 8) were significantly increased due to the condensate
255 formation of N protein-deaminases (Fig. 2j and 2k), strongly suggesting that C-to-U (T)
256 and A-to-I (G) mutations by APOBECs and ADARs may contribute to the increased
257 fitness for SARS-CoV-2. These results demonstrated that N protein penetrated into
258 deaminase-involved RNA granule to further promote SARS-CoV-2 RNA mutagenesis
259 and evolution.

260 G3BP1/2 function as the core proteins to assemble SGs and the cells lacking G3BPs
261 fail to form SGs in response to arsenite treatment³⁶. To further dissect the role of RNA-
262 deaminases condensates in host deaminase activity, we used CRISPR/Cas9 to generate
263 HeLa cells harboring the double knockout of G3BP1 and G3BP2 (referred as G3BP1/2
264 dKO, Supplementary Fig. S5a) and transfected N gene to assess the RNA mutagenesis

265 of N gene. Consistent with the previous study³⁶, HeLa cells with G3BP1/2 dKO failed
266 to form SGs after arsenite treatment (Supplementary Fig. S5b and S5c), and thereby
267 destroying the condensate formation of N protein-deaminases (Fig.3a). Notably, the
268 disruption of N protein-deaminases condensates impaired the APOBECs and ADARs-
269 mediated RNA-editing efficiency (Fig. 3b and 3c). Thus, these results further revealed
270 that N protein penetrated into deaminases-involved RNA granules to form N protein-
271 deaminases condensates, which enhanced deaminase activity to facilitate RNA
272 mutagenesis and evolution of SARS-CoV-2.

273 In addition, we similarly used CRISPR/Cas9 to generate HeLa cells with the double
274 knockout of ADAR1 and ADAR2 (referred as ADAR1/2 dKO; Supplementary Fig. S5d)
275 and transfected N gene to investigate the RNA mutagenesis of N gene. Importantly,
276 ADAR1/2 dKO indeed decreased the SNVs number of A>G/T>C transitions (Fig. 3d),
277 supporting our hypothesis that ADARs is involved in SARS-CoV-2 mutagenesis. To
278 exclude the possibility that RNA mutation with A>G/T>C was induced by stress
279 stimulation, we treated ADAR1/2 dKO HeLa cells with stress stimulator. ADAR1/2
280 dKO is unable to abolish SG formation, and N protein still possess the ability to localize
281 in SGs under the stress condition (Supplementary Fig. S5e). However, the condensates
282 formation failed to recover the A>G/T>C mutation of SNVs on the RNA of N gene,
283 even under the stress condition (Fig. 3e), suggesting that condensates act as a
284 contributor instead of an inducer on ADAR-induced A>G/T>C mutation.

285 **RNA binding domain is required for ADAR2 to form RNA-protein condensates** 286 **with N protein**

287 ADAR1/2 consist two or more double-stranded RNA binding domains (dsRBDs) and
288 a C-terminal adenosine-deaminase domain¹⁷. ADAR1 is ubiquitously distributed across
289 several tissues, and ADAR2 is abundantly expressed in the lung, urinary bladder and
290 cerebellum⁴⁵. To identify the contribution of individual domains of ADARs to
291 interaction with N protein and condensate formation, we chose ADAR2 and generated
292 various truncated mutant constructs, including dsRBD1 (RNA binding domain 1, aa78-
293 142), dsRBD2 (RNA binding domain 2, aa230-296), deaminase domain (aa317-710),

294 Δ dsRBD1 (lack of dsRBD1), Δ dsRBD2 (lack of dsRBD2) and Δ Dea (lack of
295 deaminase domain) (Fig. 4a). We found dsRBD1 alone showed a high level of
296 interaction with N protein (Fig. 4a). On the contrary, dsRBD2 or deaminase domain
297 alone failed to form protein complex with N protein. Furthermore, deletion of dsRBD1
298 completely abolished the ADAR2 interaction with N protein (Fig. 4a). The mutants of
299 Δ dsRBD2 and Δ Dea, which contain dsRBD1, possessed the ability of ADAR2
300 interaction with N protein (Fig. 4a), implying that dsRBD1 is the domain of ADAR2,
301 responsible for forming protein complex with N protein. Next, we assessed the domains
302 of ADAR2 involved in the co-localization with N protein in SGs. Consistent with the
303 result of interaction assay, dsRBD1 co-localized with N protein in SGs and ADAR2
304 lacking dsRBD1 failed to form proteins condensates with N protein (Fig. 4b;
305 Supplementary Fig. S6), illustrating that dsRBD1 is essential for ADAR2 to form the
306 condensates with N protein. SG assembly is regulated by phase separation and N
307 protein phase separated with G3BP1 into SGs^{33, 36}. ADAR2-N protein complex
308 involved in SGs inspired us to investigate whether ADAR2 exhibits features of liquid-
309 like condensates. Due to the specific function of ADAR2-dsRBD1 on interaction and
310 SG localization, recombinant GFP-dsRBD1 fusion protein was purified from *E. coli*.
311 We found, ADAR2-dsRBD1 alone was unable to induce phase separation (Fig. 4c and
312 4d). To test whether RNA binding induces phase separation of ADAR2-dsRBD1 in vitro,
313 similar to other RNA binding protein, we incubated GFP-dsRBD1 protein with RNA
314 extracted from HeLa cells. Upon mixing, ADAR2-dsRBD1 rapidly formed
315 micrometer-sized liquid droplets, accompanied by increased fluorescence intensity and
316 larger droplet area (Fig. 4c and 4d). Fluorescence recovery after photobleaching (FRAP)
317 analysis revealed that GFP-dsRBD1 diffused rapidly within droplets and exhibited
318 liquid-like property (Fig. 4e). Furthermore, N protein partitioned into dsRBD1-RNA
319 droplets and enhanced phase separation (Fig. 4f and 4g). Taken together, these results
320 revealed that N protein-ADAR2 underwent an RNA-dependent phase separation to
321 form RNA-protein condensates.

322 **The disruption of N protein-localized in SGs attenuates the viral RNA mutagenesis**

323 Our previous study revealed that N protein interaction with G3BPs is prerequisite for
324 N protein-localized in SGs, and the first intrinsically disordered region (IDR1) is
325 required for N protein to interact with G3BP1 and localize in SGs³³. Furthermore, the
326 F17A mutation in IDR1 of N protein almost abolished the N-G3BP1 interaction⁴⁶, which
327 implies N protein with F17A mutation (termed as N^{F17A} protein) may fail to form RNA-
328 protein condensates and localize in SGs. To further establish the effect of RNA-
329 deaminase condensates on the viral RNA mutagenesis, we first assessed the ability of
330 N^{F17A} protein localization in SGs. We constructed GFP-tagged N^{F17A} protein and
331 performed Co-IP assays in HeLa cells (Fig. 5a). Consistent with the reported results of
332 GST pull-down assay⁴⁶, the F17A mutation significantly impaired the N protein-G3BP1
333 interaction (Supplementary Fig. S7a), which then significantly weakened the ability of
334 N^{F17A} protein to phase separate with G3BP1 and resulted in mislocalization of N^{F17A}
335 protein in SGs (Fig. 5a-5c; Supplementary Fig. S7b and S7c). We next determined
336 whether the F17A mutation affect the interaction between N protein and host
337 deaminases. Intriguingly, the F17A mutation did not change N protein-ADAR2/A3G
338 interaction (Fig. 5d), suggesting that ITFG motif is a specific region of N protein to
339 interacted with G3BP1, instead of deaminases. However, the lack of N protein in RNA-
340 granules resulted in the failure of N protein to form RNA-protein condensates with
341 ADAR2 (Fig. 5e), which further weakened the interaction between ADAR2 and the
342 RNA of N gene. Next, we examined whether blocking N protein to entry into
343 deaminase-involved RNA granules affects deaminases-mediated the RNA editing
344 activity of N gene. To this end, we transfected N WT or N^{F17A} gene into HeLa cells and
345 then induced SG formation. Remarkably, N protein-ADAR2 complex unable to form
346 condensates severely attenuated the interaction level between host deaminase and the
347 RNA of N gene, and then impaired host deaminase -mediated RNA-editing ability (Fig.
348 5f and 5g).

349 Next, we further utilized an N^{F17A}-based transcomplementation SARS-CoV-2 cell
350 culture model to characterize the role of N-deaminase complex-involved RNA
351 condensates in deamination activity on SARS-CoV-2 genome. In agreement with the

352 mutational results of SARS-CoV-2 based on WT N protein, F17A mutation did not
353 change the mutational signature that APOBEC-mediated C-to-U (C>T/G>A) and
354 ADAR-mediated A-to-I (A>G/T>C) occupy the predominant proportion in mutational
355 ratio (Supplementary Fig. S7d), since N^{F17A} protein possessed the capability to interact
356 with host deaminases. Importantly, F17A mutation in N protein remarkably decreased
357 the ratio of T>C and C>T/G>A changes, and weakened the function of deaminase on
358 viral mutagenesis, which abolished the enrichment ratio of SNVs (A19736G and
359 C27970T) induced by deamination activity (Fig. 5h and 5i). Collectively, these results
360 demonstrated that the condensate formation of RNA-N-deaminase complex is critical
361 for the SARS-CoV-2 mutagenesis.

362 **Discussion**

363 In host-virus interaction, APOBEC and ADAR-mediated RNA editing often function
364 as the host immune response against viral infection^{13,20,47}. Conversely, viruses exploit
365 host deaminases to drive genetic diversity and achieve viral evolution^{48,49}. Here, we
366 utilized an N protein based transcomplementation SARS-CoV-2 cell culture model to
367 fully characterize the RNA mutational signature of SARS-CoV-2, providing the
368 experimental evidences that host deaminases-mediated RNA editing is able to enhance
369 viral mutation and drive virus evolution. Mechanistically, we demonstrated that N
370 protein acts as a bridge to guide host deaminases to target viral RNA for editing.
371 Furthermore, N protein penetrates into deaminase-involved RNA granule via RNA-
372 dependent phase separation to form N protein-deaminase condensates, an
373 organizational strategy that not only concentrates RNAs and proteins but also promotes
374 deaminases-induced RNA editing efficiency to viral genome. More importantly, N
375 protein^{F17A} fails to entry into deaminases-involved RNA granule, which greatly impairs
376 host deaminases activity to viral RNA, further establishing the role of N protein-
377 deaminases condensates in viral RNA mutation (Fig. 6). Our findings thus highlight a
378 mechanism involving phase separation-regulated N protein-deaminases condensation
379 that enables deaminases to drive viral mutation and evolution.

380 RNA virus mutations are often arisen from spontaneous random errors during viral

381 replication and host-driven antiviral defense systems. Coronaviruses have proof-
382 reading machinery in viral replication achieved by nsp14 exonuclease, thus possessing
383 a relatively high fidelity in viral transcription and replication processes³⁴. However, the
384 persistent accumulation of new mutations in SARS-CoV-2 genome implies host-driven
385 forces involving in viral genome mutation. Here, we examined SARS-CoV-2 RNA
386 sequence in cell culture and found the A-to-I (G) and C-to-U (T) mutation account for
387 the predominant mutational patterns, which is consistent with database analysis of
388 SARS-CoV-2 genomic variations and RNA sequence analysis from COVID-19
389 patients^{13, 14}, suggesting host antiviral response via APOBEC and ADAR-mediated
390 RNA editing is the one of drivers for SARS-CoV-2 genome mutation. Moreover, the
391 number of APOBEC or ADAR-induced SNVs on SARS-CoV-2 genome was
392 significantly decreased after several passages, demonstrating that the deaminases
393 function as host antiviral response to induce the extensive mutation of SARS-CoV-2
394 RNA in the early viral infection, which may lead to viral RNA degradation and inhibit
395 viral RNA replication. However, SARS-CoV-2 is likely to express functional protein to
396 combat host restriction factors and weaken the deaminases activity, which lead to the
397 reduced the number of SNVs in SARS-CoV-2 genome. The similar process has been
398 previous reported for APOBEC3G, a powerful arm of the host defence against HIV and
399 other retroviruses via bringing “typographical errors” during viral replication⁵⁰⁻⁵². On
400 the contrary, HIV-encoded virion infectivity factor (Vif) induces APOBEC3G
401 degradation and protects the virus from APOBEC3G-induced inactivation⁵². However,
402 the frequency of the SNVs in undegraded viral RNA was greatly promoted, suggesting
403 SARS-CoV-2 in turn utilizes host deaminases-mediated RNA editing to fuels its
404 evolution. Another interesting feature is that the transversions of G-to-U (G>T) and C-
405 to-A (C>A) are the second main group for nucleotides C and G mutation, which was
406 possibly associated with the mutagenic activity of ROS^{16, 28}. Furthermore, the
407 transversions of A-to-U (A>T) and U-to-A (T>A) on SARS-CoV-2 genomes appear in
408 the second main group for nucleotides A and T change, but the mechanistic basis for
409 this process is currently unknown and still need to be further studied. Thus, the
410 mutational outcome of SARS-CoV-2 genome are controlled by multi-driving forces

411 from host and virus.

412 For RNA-protein interaction, the SARS-CoV-2 N protein, which binds the viral RNA,
413 was reported to be a most significantly enriched viral protein in SARS-CoV-2 RNA
414 purifications⁵³. ADARs were identified as the SARS-CoV-2 RNA binder in host cell
415 proteins⁵³. For protein-protein interaction, APOBEC3G associated with coronavirus N
416 protein to package into SARS-CoV virus-like particles⁵⁴. A SARS-CoV-2 protein
417 interaction map revealed N protein interacted with several RNA binding proteins³⁴.
418 Although several clues were shown to be implied in deaminases targeting viral RNA,
419 the precise mechanism remains elusive. In this study, we demonstrated that N protein,
420 but not other viral SARS-CoV-2 RNA binders, interacted with host deaminases
421 containing APOBEC1, AID, APOBEC3D, APOBEC3F, APOBEC3G, APOBEC3H,
422 ADAR1 and ADAR2, suggesting that N protein acts as a specific protein binder for
423 host deaminases and viral RNA, and then link them together. For APOBECs family,
424 only APOBEC1, APOBEC3A and APOBEC3G are shown to possess RNA editing
425 activities^{24, 26, 55, 56}. The further study need to be perform to identify the member of host
426 deaminases which indeed target SARS-CoV-2 RNA and edit viral RNA.

427 Membraneless organelles, serve as an alternative approach to concentrate specific
428 proteins and nucleic acids and increase the local concentration, thereby significantly
429 strengthening binding affinity^{44, 57-59}. Consistently, we observed that the condensate
430 formation of N protein-deaminases complex enable ADAR2 to bind more RNA of N
431 protein. The biological function of specific molecular-enriched condensates is to amplify
432 signals and accelerate the reaction rate⁵⁸. Notably, we showed that N protein penetrates
433 into deaminases-involved RNA granule to form N protein-deaminases condensates,
434 which greatly promoted the RNA mutational rate of N protein. Conversely, N^{F17A} failed
435 to be recruited into deaminases-involved RNA granule, which dramatically reduced the
436 RNA editing efficiency of deaminases. The potential mechanism is that RNA granule,
437 as a condense organization, increases the local concentration of viral RNA and
438 deaminases to enhance deamination activity. These results suggest that phase separation
439 may serve as a regulatory mechanism to control the deamination activity, and provide

440 a novel organizational strategy to promote viral RNA editing efficiency via
441 concentrating RNAs and deaminases. However, phase separation-mediated
442 condensation often acts as a double edged sword for regulating bimolecular activity.
443 Phase separation forms a selective environment that limit catalytic function of the
444 cytosolic exonuclease TREX1⁶⁰. RNA polymerization are inhibited in the polyamine-
445 containing condensation⁶¹. On the contrary, polyethylene glycol (PEG)/dextran
446 aqueous two-phase system (ATPS)-mediated phase separation greatly increased RNA
447 catalytic reaction⁶². Thus, understanding the physicochemical features of micro-
448 condensates containing the size, chemical makeup and the structure stability is
449 necessary for predictions of deamination activity.

450 In summary, we here provide the experimental evidences that host deaminases function
451 as the driving force to induce mutation of SARS-CoV-2 genome. During this process,
452 N protein acts as a bridge to guide deaminases to target viral RNA. Furthermore, virus
453 exploits host RNA granule to promote deaminases-mediated RNA editing activity and
454 fuel its evolution. These insights help to predict viral mutation trend, and also provide
455 new insights into SARS-CoV-2 therapeutic development.

456 **Methods**

457 **Plasmid construction.** DNA fragments encoding the APOBEC family proteins, ADAR
458 family proteins and SARS-CoV-2 proteins annotated in this manuscript were
459 synthesized by Genscript and amplified by PCR using Phanta® Max Super-Fidelity
460 DNA Polymerase (Vazyme, P505-d1). While the coding region of ADAR2 deletions
461 were amplified by PCR from a plasmid containing full-length ADAR2 with appropriate
462 sets of primers. Exnase (Vazyme, C214-02-AF) was used to insert these sequences into
463 one of the following backbone: CMV-mCherry-Flag, CMV-mCherry-HA, CMV-BFP-
464 Flag, CMV-BFP-HA, CMV-GFP, CMV-Flag. All plasmid inserts were confirmed by
465 BioSune Sanger sequencing.

466 **Cell culture, transfection, and harvest.** HeLa cells were cultured in DMEM medium
467 supplemented with 10% bovine growth serum and 1% penicillin/streptomycin at 37 °C
468 in a 5% CO₂ humidified incubator. For plasmid transfection, cells were seeded on 6-

469 well plates and transfected at approximately 70% confluence using Lipofectamin 3000
470 reagent (Invitrogen, L3000008). 48 h after transfection, cells were collected from
471 Fluorescence Activating Cell Sorter (FACS) according to the fluorescence driven by
472 the transfected plasmid.

473 **Generation of G3BP1/2 or ADAR1/2 knock-out cell lines.** HeLa cells were seeded
474 in a 24-well plate and transfected with 300 ng sgRNA and 700 ng spCas9 plasmid using
475 Lipofectamine 3000 transfection kit (Invitrogen, L3000015). 48 h after transfection,
476 cells were sorted in 96-well plates using fluorescence-activated cell sorting (FACS).
477 The genomic DNA of edited cells was extracted using QuickExtract™ DNA Extraction
478 Solution (Lucigen, QE09050), the sequences of interest was amplified by PCR and
479 analyzed by BioSune Sanger sequencing. While individual clones were lysed in RIPA
480 buffer (Beyotime, P0013B) contained with 1 mmol/L phenylmethanesulfonyl fluoride
481 (PMSF) and 1% (v/v) protease inhibitor cocktail (Thermo Fisher scientific, 78443) on
482 ice for 15 min. The lysate was centrifuged at 12,000 rpm for 15 min at 4 °C. The
483 supernatant was harvested and used for SDS-PAGE analyzed with G3BP1 antibody
484 (proteintech, 66486-1-Ig), G3BP2 antibody (proteintech, 16276-1-AP), ADAR1
485 antibody (proteintech, 14330-1-AP) and ADARB1 antibody (proteintech, 22248-1-AP),
486 respectively. The sgRNAs used are listed in Supplementary Table 1.

487 **Co-immunoprecipitation.** Plasmids were transfected into HeLa cells using
488 Lipofectamin 3000 reagent (Invitrogen, L3000008). 48 h after transfection, cells were
489 harvested and lysed with RIPA buffer (Beyotime, P0013B) contained with 1 mmol/L
490 PMSF and 1% (v/v) protease inhibitor cocktail (Thermo Fisher scientific, 78443). The
491 cell lysates were incubated on ice for 15 min and centrifuged at $16,000 \times g$ at 4 °C for
492 20 min, the supernatant was incubated with pre-equilibrated anti-flag beads (Bimake,
493 B26101) or anti-GFP beads (KT Health, KTSM1333) for 4 h at 4 °C. Then, the beads
494 were washed three times with PBS supplemented with 0.05% (V/V) Tween-20 to
495 remove nonspecific binding proteins. 1 × loading buffer containing SDS were added
496 into each sample and heated at 98 °C for 10 min to elute bound proteins. The
497 supernatant was harvested and used for SDS-PAGE analysis.

498 **RNA immunoprecipitation (RIP) assays.** Plasmids encoding the DNA fragments of

499 N wild type or N^{F17A} mutant were transfected into HeLa cells, the experiments were
500 performed using RIP assay kit (Genesee Biotech, P0102) according to the
501 manufacturer's instructions with the following antibodies: rabbit anti-ADARB1
502 (Proteintech, 22248-1-AP) and normal rabbit IgG (Abcam, ab190475). The
503 immunoprecipitated RNA was purified and analyzed by RT-qPCR, sequences for
504 primers are listed in Supplementary Table 2.

505 **Immunofluorescence.** HeLa cells were seeded to reach 60% confluence and
506 transfected with plasmids in 24-well glass bottom plates (Cellvis, Mountain View,
507 USA). To induce SGs, the cells were treated with 200 µmol/L sodium arsenite for 45
508 min. The cells were fixed in 4% paraformaldehyde for 15 min at room temperature and
509 washed three times with PBS. After incubated with blocking buffer (5% (v/v) normal
510 goat serum (Bioss Antibodies, C-0005), 0.3% (v/v) Triton X-100, 94.7% (v/v) PBS) for
511 2 h at room temperature, cells were incubated with primary antibodies against G3BP1
512 (Proteintech, 66486-1-Ig; 1:200 dilution), TIA1 (Proteintech, 12133-2-AP; 1:200
513 dilution) or Flag (Cell Signaling Technology, 14793s; 1:1000 dilution) overnight at 4 °C.
514 The cells were washed three times in PBS and incubated with Alexa Fluor 488/647
515 conjugated secondary antibodies for 1 h. Cell nuclei were stained with 4,6-diamidino-
516 2-phenylindole (DAPI; Yeasen, 40728ES03). Images were acquired with a Nikon
517 spinning disk microscope.

518 **Western blotting.** The same amount of protein samples were separated by SDS-PAGE
519 and transferred to methanol-activated polyvinylidene fluoride (PVDF) membranes
520 (Millipore, IPVH00010). The membranes were blocked for 1 h at room temperature in
521 Tris-buffered saline and 0.1% Tween-20 (TBST) containing 5% (wt/vol) nonfat milk.
522 After that, the membranes were incubated with primary antibodies with the dilution
523 ratio according to manufacturer's instruction at 4 °C overnight. The membranes were
524 washed three times in TBST and the protein bands were detected with horse radish
525 peroxidase-conjugated secondary antibodies and Immobilon Western enhanced
526 chemiluminescent solution (Millipore, WBKLS0100). The protein levels were
527 normalized by probing the same blots with GAPDH antibody (Absin, abs132004;
528 1:5000 dilution).

529 **SARS-CoV-2 GFP/ Δ N trVLP infection.** Caco-2 cells expressing WT N protein are
530 infected with SARS-CoV-2 GFP/ Δ N P1 trVLP²⁹ at MOI of 0.1. 24 hours post infection,
531 cells are washed with Dulbecco's Phosphate-Buffered Saline (DPBS) and collected
532 with TRIzol reagent (Invitrogen, 15596018). Uninfected Caco-2 cells expressing WT
533 N protein are mock control.

534 **SARS-CoV-2 GFP/ Δ N trVLP passage.** SARS-CoV-2 GFP/ Δ N P0 trVLPs²⁹ are used
535 to infect Caco-2 cells expressing WT N protein or F17A mutant N protein at a
536 multiplicity of infection (MOI) of 0.1 for 24 hours, supernatants (P1) are collected to
537 further infect Caco-2 cells expressing WT N protein or F17A mutant N protein. Cell
538 cultures collected from each subsequent passage on the Caco-2-N WT or F17A mutant
539 cells were defined as P1 to P6, respectively. Cells are washed with DPBS and collected
540 with Trizols (Invitrogen, 15596018).

541 **SARS-CoV-2 mutation analysis.** Total viral RNA in the supernatant were extracted
542 using TRIzol reagent (Invitrogen, 15596018). Complementary DNA (cDNA) was
543 synthesized from RNA using the HiScript III 1st Strand cDNA synthesis Kit (Vazyme,
544 R312-01). Libraries were generated using the TruePrepTM DNA Library Prep Kit V2
545 for Illumina (Vazyme, TD503-01) and sequenced by Illumina Hiseq X Ten platform.
546 The RNA-seq data were aligned to the SARS-CoV-2 reference genome (NC_045512)
547 using STAR software (Version 2.5.1).

548 Plasmids encoding the DNA fragment of SARS-CoV-2 genes were transfected into
549 HeLa cells. 48 h after transfection, cells were treated with 120 μ mol/L sodium arsenite
550 to generate stress granules for 10 h. Then, cells were harvested and the RNA was
551 extracted by TRIzol reagent (Invitrogen, 15596018). 1 μ g RNA was reversely
552 transcribed into cDNA using Reverse Transcriptase (Vazyme, R223-01-AB). The target
553 sites were amplified with Phanta Max Super-Fidelity DNA Polymerase (Vazyme, P505-
554 d1) and subjected to high-throughput sequencing with the Illumina Hiseq X Ten
555 platform. Sequences for primers are listed in Supplementary Table 3. The preprocessed
556 data were then aligned to the plasmids sequence using bwa software (Version 0.7.17).
557 All variants from RNA-seq and deep-seq were identified and calculated using bam-
558 readcount with parameters $-q$ 20 $-b$ 30. The SNVs filter is based on a minimum

559 threshold of 20 reads.

560 **Protein purification.** DNA fragments encoding the proteins of interest were cloned
561 into pET-28a vector. Proteins were expressed in *E. coli* BL21 (DE3) (Trans, CD601).
562 *E. coli* were induced with 1.0 mmol/L IPTG at 16 °C for 14 h. Cells were ultrasonic
563 broken down centrifuged, the supernatant was collected and added 0.4 µg/mL DNase
564 and RNAase to remove the possible bound DNA and RNA to the protein. The interest
565 protein was purified by Ni resin (TaKaRa, 635660) and AEKTA purifier. The purified
566 protein was stored in 20 mM Tris (pH 8.4), 500 mM NaCl, 10% (v/v) glycerol at -80 °C
567 before further analysis.

568 **Fluorescence recovery after photobleaching (FRAP) analysis.** FRAP analysis was
569 performed using the Nikon Spinning Disk microscope equipped with two laser systems.
570 1-2 images were acquired before the center of the indicated protein droplets was
571 bleached with laser at 488 nm. Images were collected every 10 s for 2 min after
572 photobleaching.

573 **Statistical analysis.** All statistical analyses were done using OriginPro (2019b,
574 OriginLab, Northampton, USA) or Microsoft Excel (Professional 2019, Microsoft
575 Corporation, Redmond, USA). The outcomes of all statistical tests including number
576 of samples and *P* values were revealed in the corresponding figure legends. Results
577 were presented as mean ± SEM. The significance of *P* values is represented as follows:
578 ns > 0.05, **P* < 0.05; ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001, ns, no significant.

579 **Acknowledgements**

580 We thank all members of Huang lab for helpful discussions and Dr. Haitao Yang from
581 ShanghaiTech University for insightful discussion; Molecular Imaging Core Facility
582 and Molecular and Cellular Biology Core Facility for support with imaging and cellular
583 biology experiments. This work is supported by the National Key R&D Program of
584 China (2021YFA0804702), the leading talents of Guangdong province program
585 (2016LJ06S386), National Natural Science Foundation of China (22177073),
586 Emergency Key Program of Guangzhou Laboratory (EKPG21-18), National Natural
587 Science Foundation of China (32070153), Tsinghua University Spring Breeze Fund
588 (2021Z99CFY030) and Beijing Municipal Natural Science Foundation (M21001).

589 **Author contributions**

590 Y.Z., X.H., C.H. and Q.D. conceived and designed the entire project. Y.Z., Z.L. and L.L.
591 supervised and performed the bulk of the experiments and analyzed nearly all
592 experimental data. L.L. generated constructs and cell lines. S.H. analyzed next-
593 generation sequencing data. Z.L. and L.L. assisted with imaging experiments. X.J. and
594 Q.D. prepared all viral RNA sample of the SARS-CoV-2 for next-generation
595 sequencing. Y.Z., Z.L. and L.L. wrote the manuscript. All authors contributed idea and
596 reviewed the manuscript.

597 **Data availability**

598 Sequence data were submitted to NCBI and are accessible with BioProject ID:
599 PRJNA824251. The data that support the findings of this study are available from the
600 corresponding author upon reasonable request.

601 **Conflict of Interest**

602 The authors declare no conflict of interest.

603 **References**

- 604 1. Tegally, H. *et al.* Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature*
605 **592**, 438-+ (2021).
- 606 2. Schmidt, F. *et al.* Plasma Neutralization of the SARS-CoV-2 Omicron Variant. *New Engl J*
607 *Med* **386**, 599-601 (2022).
- 608 3. Karim, S.S.A. & Karim, Q.A. Omicron SARS-CoV-2 variant: a new chapter in the COVID-
609 19 pandemic. *Lancet* **398**, 2126-+ (2021).
- 610 4. Muik, A. *et al.* Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2
611 vaccine-elicited human sera. *Science* **371**, 1152-+ (2021).
- 612 5. Maxmen, A. Omicron Blind Spots: Why It's Hard to Track Coronavirus Variants. *Nature*
613 **600**, 579-579 (2021).
- 614 6. WHO. Coronavirus (COVID-19) Dashboard. <https://covid19.who.int/>. (2022).
- 615 7. Dejnirattisai, W. *et al.* Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant
616 by post-immunisation serum. *Lancet* **399**, 234-236 (2022).
- 617 8. Collie, S., Champion, J., Moultrie, H., Bekker, L.G. & Gray, G. Effectiveness of BNT162b2
618 Vaccine against Omicron Variant in South Africa. *New Engl J Med* **386**, 494-496 (2022).
- 619 9. Liu, L.H. *et al.* Striking antibody evasion manifested by the Omicron variant of SARS-CoV-
620 2. *Nature* (2021).
- 621 10. Hu, J. *et al.* Increased immune escape of the new SARS-CoV-2 variant of concern Omicron.
622 *Cell Mol Immunol* **19**, 293-295 (2022).
- 623 11. Yin, W.C. *et al.* Structural basis for inhibition of the RNA-dependent RNA polymerase from
624 SARS-CoV-2 by remdesivir. *Science* **368**, 1499-+ (2020).

- 625 12. Maio, N. *et al.* Fe-S cofactors in the SARS-CoV-2 RNA-dependent RNA polymerase are
626 potential antiviral targets. *Science* **373**, 236-+ (2021).
- 627 13. Wang, R., Hozumi, Y., Zheng, Y.H., Yin, C.C. & Wei, G.W. Host Immune Response Driving
628 SARS-CoV-2 Evolution. *Viruses-Basel* **12** (2020).
- 629 14. Di Giorgio, S., Martignano, F., Torcia, M.G., Mattiuz, G. & Conticello, S.G. Evidence for host-
630 dependent RNA editing in the transcriptome of SARS-CoV-2. *Science Advances* **6** (2020).
- 631 15. Zhang, Y.P. *et al.* Fast evolution of SARS-CoV-2 driven by deamination systems in hosts.
632 *Future Virol* **16**, 587-590 (2021).
- 633 16. Mourier, T. *et al.* Host-directed editing of the SARS-CoV-2 genome. *Biochem Bioph Res*
634 *Co* **538**, 35-39 (2021).
- 635 17. Rusk, N. RNA editing with endogenous ADAR. *Nat Methods* **16**, 285-285 (2019).
- 636 18. Roth, S.H., Levanon, E.Y. & Eisenberg, E. Genome-wide quantification of ADAR adenosine-
637 to-inosine RNA editing activity. *Nat Methods* **16**, 1131-+ (2019).
- 638 19. Piontkivska, H., Frederick, M., Miyamoto, M.M. & Wayne, M.L. RNA editing by the host
639 ADAR system affects the molecular evolution of the Zika virus. *Ecol Evol* **7**, 4475-4485
640 (2017).
- 641 20. Samuel, C.E. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral.
642 *Virology* **411**, 180-193 (2011).
- 643 21. Salter, J.D., Bennett, R.P. & Smith, H.C. The APOBEC Protein Family: United by Structure,
644 Divergent in Function. *Trends Biochem Sci* **41**, 578-594 (2016).
- 645 22. Stavrou, S. & Ross, S.R. APOBEC3 Proteins in Viral Immunity. *J Immunol* **195**, 4565-4570
646 (2015).
- 647 23. Bishop, K.N., Holmes, R.K., Sheehy, A.M. & Malim, M.H. APOBEC-mediated editing of viral
648 RNA. *Science* **305**, 645-645 (2004).
- 649 24. Sharma, S. *et al.* APOBEC3A cytidine deaminase induces RNA editing in monocytes and
650 macrophages. *Nature Communications* **6** (2015).
- 651 25. Dance, G.S.C., Sowden, M.P., Yang, Y. & Smith, H.C. APOBEC-1 dependent cytidine to
652 uridine editing of apolipoprotein B RNA in yeast. *Nucleic Acids Research* **28**, 424-429
653 (2000).
- 654 26. Sharma, S., Patnaik, S.K., Taggart, R.T. & Baysal, B.E. The double-domain cytidine
655 deaminase APOBEC3G is a cellular site-specific RNA editing enzyme. *Sci Rep-Uk* **6** (2016).
- 656 27. Valyi-Nagy, T. & Dermody, T.S. Role of oxidative damage in the pathogenesis of viral
657 infections of the nervous system. *Histol Histopathol* **20**, 957-967 (2005).
- 658 28. Smith, E.C. The not-so-infinite malleability of RNA viruses: Viral and cellular determinants
659 of RNA virus mutation rates. *Plos Pathogens* **13** (2017).
- 660 29. Ju, X.H. *et al.* A novel cell culture system modeling the SARS-CoV-2 life cycle. *Plos*
661 *Pathogens* **17** (2021).
- 662 30. Eggington, J.M., Greene, T. & Bass, B.L. Predicting sites of ADAR editing in double-
663 stranded RNA. *Nature Communications* **2** (2011).
- 664 31. Bass, B.L. RNA editing by adenosine deaminases that act on RNA. *Annu Rev Biochem* **71**,
665 817-846 (2002).
- 666 32. Rosenberg, B.R., Hamilton, C.E., Mwangi, M.M., Dewell, S. & Papavasiliou, F.N.
667 Transcriptome-wide sequencing reveals numerous APOBEC1 mRNA-editing targets in
668 transcript 3' UTRs. *Nature Structural & Molecular Biology* **18**, 230-U300 (2011).

- 669 33. Luo, L.L. *et al.* SARS-CoV-2 nucleocapsid protein phase separates with G3BPs to
670 disassemble stress granules and facilitate viral production. *Sci Bull* **66**, 1194-1204 (2021).
- 671 34. Gordon, D.E. *et al.* A SARS-CoV-2 protein interaction map reveals targets for drug
672 repurposing. *Nature* (2020).
- 673 35. Buchan, J.R. & Parker, R. Eukaryotic stress granules: the ins and outs of translation. *Mol*
674 *Cell* **36**, 932-941 (2009).
- 675 36. Yang, P. *et al.* G3BP1 Is a Tunable Switch that Triggers Phase Separation to Assemble
676 Stress Granules. *Cell* **181**, 325-345 e328 (2020).
- 677 37. Tsai, W.C. & Lloyd, R.E. Cytoplasmic RNA Granules and Viral Infection. *Annu Rev Virol* **1**,
678 147-170 (2014).
- 679 38. Onomoto, K., Yoneyama, M., Fung, G., Kato, H. & Fujita, T. Antiviral innate immunity and
680 stress granule responses. *Trends Immunol* **35**, 420-428 (2014).
- 681 39. White, J.P. & Lloyd, R.E. Regulation of stress granules in virus systems. *Trends Microbiol*
682 **20**, 175-183 (2012).
- 683 40. Lloyd, R.E. Regulation of stress granules and P-bodies during RNA virus infection. *Wiley*
684 *Interdiscip Rev RNA* **4**, 317-331 (2013).
- 685 41. Zheng, Z.Q., Wang, S.Y., Xu, Z.S., Fu, Y.Z. & Wang, Y.Y. SARS-CoV-2 nucleocapsid protein
686 impairs stress granule formation to promote viral replication. *Cell Discov* **7**, 38 (2021).
- 687 42. Banani, S.F., Lee, H.O., Hyman, A.A. & Rosen, M.K. Biomolecular condensates: organizers
688 of cellular biochemistry. *Nat Rev Mol Cell Bio* **18**, 285-298 (2017).
- 689 43. Tsang, B. *et al.* Phosphoregulated FMRP phase separation models activity-dependent
690 translation through bidirectional control of mRNA granule formation. *P Natl Acad Sci USA*
691 **116**, 4218-4227 (2019).
- 692 44. Kent, S. *et al.* Phase-Separated Transcriptional Condensates Accelerate Target-Search
693 Process Revealed by Live-Cell Single-Molecule Imaging. *Cell Reports* **33** (2020).
- 694 45. Chen, G.H., Katrekar, D. & Mali, P. RNA-Guided Adenosine Deaminases: Advances and
695 Challenges for Therapeutic RNA Editing. *Biochemistry* **58**, 1947-1957 (2019).
- 696 46. Huang, W.J. *et al.* Molecular determinants for regulation of G3BP1/2 phase separation by
697 the SARS-CoV-2 nucleocapsid protein. *Cell Discov* **7** (2021).
- 698 47. Olson, M.E., Harris, R.S. & Harki, D.A. APOBEC Enzymes as Targets for Virus and Cancer
699 Therapy. *Cell Chem Biol* **25**, 36-49 (2018).
- 700 48. Wang, W.Q., Zhao, H.Y. & Han, G.Z. Host-Virus Arms Races Drive Elevated Adaptive
701 Evolution in Viral Receptors. *Journal of Virology* **94** (2020).
- 702 49. Dolja, V.V. Virus-host arms race as a shaping force of virus evolution. *Phytopathology* **99**,
703 S165-S165 (2009).
- 704 50. Mangeat, B. *et al.* Broad antiretroviral defence by human APOBEC3G through lethal
705 editing of nascent reverse transcripts. *Nature* **424**, 99-103 (2003).
- 706 51. Esnault, C. *et al.* APOBEC3G cytidine deaminase inhibits retrotransposition of endogenous
707 retroviruses. *Nature* **433**, 430-433 (2005).
- 708 52. Sheehy, A.M., Gaddis, N.C. & Malim, M.H. The antiretroviral enzyme APOBEC3G is
709 degraded by the proteasome in response to HIV-1 Vif. *Nature Medicine* **9**, 1404-1407
710 (2003).
- 711 53. Schmidt, N. *et al.* The SARS-CoV-2 RNA-protein interactome in infected human cells. *Nat*
712 *Microbiol* **6**, 339-+ (2021).

- 713 54. Wang, S.M. & Wang, C.T. APOBEC3G cytidine deaminase association with coronavirus
714 nucleocapsid protein. *Virology* **388**, 112-120 (2009).
- 715 55. Teng, B.B., Burant, C.F. & Davidson, N.O. Molecular-Cloning of an Apolipoprotein-B
716 Messenger-Rna Editing Protein. *Science* **260**, 1816-1819 (1993).
- 717 56. Wolfe, A.D., Arnold, D.B. & Chen, X.J.S. Comparison of RNA Editing Activity of APOBEC1-
718 A1CF and APOBEC1-RBM47 Complexes Reconstituted in HEK293T Cells. *Journal of*
719 *Molecular Biology* **431**, 1506-1517 (2019).
- 720 57. Alberti, S. Phase separation in biology. *Current Biology* **27**, R1097-R1102 (2017).
- 721 58. Antoniou, D. & Schwartz, S.D. Phase Space Bottlenecks in Enzymatic Reactions. *J Phys*
722 *Chem B* **120**, 433-439 (2016).
- 723 59. Tauber, D., Tauber, G. & Parker, R. Mechanisms and Regulation of RNA Condensation in
724 RNP Granule Formation. *Trends Biochem Sci* **45**, 764-778 (2020).
- 725 60. Zhou, W., Mohr, L., Maciejowski, J. & Kranzusch, P.J. cGAS phase separation inhibits
726 TREX1-mediated DNA degradation and enhances cytosolic DNA sensing. *Molecular Cell*
727 **81**, 739-+ (2021).
- 728 61. Drobot, B. *et al.* Compartmentalised RNA catalysis in membrane-free coacervate
729 protocells. *Nature Communications* **9** (2018).
- 730 62. Strulson, C.A., Molden, R.C., Keating, C.D. & Bevilacqua, P.C. RNA catalysis through
731 compartmentalization. *Nat Chem* **4**, 941-946 (2012).

732

733

734

735

736

737

738

739

740

741

742

743

744

745

746

747

748

749 **Figure legends**

750 **Fig. 1 SARS-CoV-2 N protein interacts with host deaminases and links deaminases**
751 **to edit viral RNA. a**, Average proportion of nucleotide changes in the SARS-CoV-2
752 transcriptomes. $n = 3$ (allelic fraction $\geq 0.1\%$). The X-axis is the original nucleotide of
753 SARS-CoV-2 genome, and indicative colour blocks represent nucleotides to which
754 original nucleotide were mutated. **b**, Sequence contexts for A-to-I (G) and C-to-U (T)
755 edited sites in viral transcriptome. **c**, Allelic fraction of SNVs identified in the SARS-
756 CoV-2 transcriptomes using SARS-CoV-2 N protein-based genetic complementation
757 system. $n = 3$ (allelic fraction $\geq 0.02\%$). **d**, The number of SNVs identified in the SARS-
758 CoV-2 transcriptomes using SARS-CoV-2 N protein-based genetic complementation
759 system after one and six passages (P1 and P6) (allelic fraction $\geq 0.1\%$, $n = 3$). Data are
760 shown as mean \pm SEM. **e**, N protein interacted with host deaminases. HeLa cells were
761 co-transfected with plasmids encoding GFP-tagged N protein and Flag control or Flag-
762 tagged host deaminases, including APOBEC1 (A1), activation-induced cytidine
763 deaminase (AID), APOBEC2 (A2), APOBEC3 (3A-3D and 3F-3H), APOBEC4 (A4),
764 ADAR1 (AD1) and ADAR2 (AD2). Cell lysates were immunoprecipitated with an anti-
765 Flag antibody and the bound proteins were then analysed by western blotting. **f**, The
766 enrichment of N protein mRNA was measured by RIP assay in HeLa cells ($n = 3$). HeLa
767 cells were transfected with N gene with GFP tag and lysates were collected 48 h after
768 transfection. Lysates were prepared and split for incubation with mouse anti-ADAR2
769 antibody. Co-precipitated RNA was analyzed by qRT-PCR ($n = 3$). Data are shown as
770 mean \pm SEM. **g**, Average proportion of nucleotide changes in the N gene in HeLa cells.
771 Cells were transfected with the N gene and then were lysed in TRIzol reagent. The
772 mRNA was reversely transcribed and cDNA were amplified. The amplicons were
773 analysed by deep sequencing. Values and error bars were represented as the mean \pm
774 SEM of three independent biological replicates (allelic fraction $\geq 0.02\%$). The X-axis
775 is the original nucleotide of N gene, and indicative colour blocks represent nucleotides
776 to which original nucleotide were mutated. **h**, ADAR2 specifically interacted with
777 SARS-CoV-2 N protein. HeLa cells were co-transfected with plasmids encoding HA-
778 tagged ADAR2 and GFP control or GFP-tagged SARS-CoV-2 genes, including nsp7

779 (n7), nsp8 (n8), nsp9 (n9), nsp12 (n12), nsp16 (n16), spike (S), E, M and N. Cell lysates
780 were immunoprecipitated with an anti-GFP antibody and the bound proteins were then
781 analysed by western blotting. Statistical analysis was performed with two-tailed
782 unpaired t-test. ns > 0.05, **P* < 0.05, ***P* < 0.01, ****P* < 0.001, *****P* < 0.0001. ns, no
783 significant.

784 **Fig. 2 The condensation of N protein-deaminases complex efficiently enhances**
785 **viral RNA mutagenesis. a**, N protein interacted with host G3BP1 and deaminase
786 APOBEC3G or ADAR2. HeLa cells were co-transfected with plasmids encoding GFP-
787 tagged N protein or GFP control and HA-tagged APOBEC3G (A3G) or ADAR2. Cell
788 lysates were immunoprecipitated with an anti-GFP antibody and the bound proteins
789 were then analysed by western blotting with antibodies against HA or G3BP1. **b**,
790 APOBEC3G or ADAR2 co-localized with N protein in stress granules in HeLa cells.
791 The HeLa cells transfected with the N gene and APOBEC3G or ADAR2 were treated
792 with sodium arsenite (AS) for 45 min to induces SG formation, followed by
793 immunostaining for the N protein (red), A3G or ADAR2 (blue) and endogenous G3BP1.
794 Scale bar: 20 μm. **c**, The condensate formation of N protein-deaminases complex
795 enhanced N protein interaction with A3G or ADAR2 protein. HeLa cells transfected
796 with N gene and Flag control or Flag-tagged deaminases, including AID, A3G, A3H
797 and ADAR2, were treated with or without AS. Cell lysates were immunoprecipitated
798 with an anti-flag antibody and the bound proteins were then analysed by Western
799 blotting. **d**, The enrichment of N protein mRNA was measured by RIP assay in HeLa
800 cells treated with or without AS treatment. HeLa cells were transfected with N gene
801 with GFP tag for 48 h and then treated with or without AS treatment for 45 min. Lysates
802 were prepared and split for incubation with mouse anti-ADAR2 antibody. Co-
803 precipitated RNA was analyzed by qRT-PCR (n = 3). Data are shown as mean ± SEM.
804 **e**, The formation of RNP condensation promoted the account of SNVs identified in the
805 N gene in HeLa cells. Cells were transfected with the N gene with or without sodium
806 arsenite (AS) for 10 h and then lysed in TRIzol reagent. The mRNA was reversely
807 transcribed and cDNA were amplified. The amplicons were analysed by deep
808 sequencing. Values and error bars were represented as the mean ± SEM of three

809 independent biological replicates (allelic fraction $\geq 0.02\%$). **f**, The formation of RNP
810 condensation promoted the account of SNVs identified in the spike gene in HeLa cells.
811 Values and error bars were represented as the mean \pm SEM of three independent
812 biological replicates (allelic fraction $\geq 0.02\%$). **g**, The formation of RNP condensation
813 promoted the account of SNVs identified in the Orf 8 in HeLa cells. Values and error
814 bars were represented as the mean \pm SEM of three independent biological replicates
815 (allelic fraction $\geq 0.02\%$). **h**, Allelic fraction of SNVs for each nucleotide change in the
816 N gene in HeLa cells treated with or without AS treatment (n = 3). Data are shown as
817 mean \pm SEM. **i**, Allelic fraction of SNVs for each nucleotide change in the spike gene
818 in HeLa cells treated with or without AS treatment (n =3). Data are shown as mean \pm
819 SEM. **j**, Allelic fraction of SNVs for A23403G (spike protein: D614G) in HeLa cells
820 (n =3). Data are shown as mean \pm SEM. Data were normalized to 100% by the allelic
821 fraction of HeLa cells without AS treatment. **k**, Allelic fraction of SNVs for C27972T
822 (ORF8:Q27*) in HeLa cells (n =3). Data are shown as mean \pm SEM. Data were
823 normalized to 100% by the allelic fraction of HeLa cells without AS treatment.
824 Statistical analysis was performed with two-tailed unpaired t-test. ns > 0.05, * P < 0.05,
825 ** P < 0.01, *** P < 0.001, **** P < 0.0001. ns, no significant.

826 **Fig. 3 The disruption of N protein/deaminases-involved condensates attenuates**
827 **viral RNA mutagenesis.** **a**, G3BP1/2 dKO abolished the formation of N
828 protein/deaminases-involved condensates. **b**, The disruption of N protein/deaminases-
829 involved condensates attenuated ADAR-mediated RNA editing. Values and error bars
830 were represented as the mean \pm SEM of three independent biological replicates (allelic
831 fraction $\geq 0.03\%$). **c**, The disruption of N protein/deaminases-involved condensates
832 attenuated APOBEC-mediated RNA editing. Values and error bars were represented as
833 the mean \pm SEM of three independent biological replicates (allelic fraction $\geq 0.03\%$). **d**,
834 ADAR1/2 dKO reduced ADAR-mediated RNA editing. Values and error bars were
835 represented as the mean \pm SEM of three independent biological replicates (allelic
836 fraction $\geq 0.03\%$). **e**, The RNP condensation failed to increase ADAR-mediated RNA
837 mutagenesis due to ADAR1/2 dKO. Values and error bars were represented as the mean
838 \pm SEM of three independent biological replicates (allelic fraction $\geq 0.03\%$). Statistical

839 analysis was performed with two-tailed unpaired t-test. ns > 0.05, * P < 0.05, ** P <
840 0.01, *** P < 0.001, **** P < 0.0001. ns, no significant.

841 **Fig. 4 RNA binding domain is required for ADAR2 to form phase separation-**
842 **mediated RNP condensates with N protein.** **a**, Characterization of ADAR2 mutants
843 required for interaction with N protein. Top, schematic domain structure of ADAR2.
844 HeLa cells were co-transfected with plasmids encoding N protein and Flag control or
845 Flag-tagged host ADAR2 truncations. Cell lysates were immunoprecipitated with an
846 anti-Flag antibody and the bound proteins were then analysed by Western blotting. **b**,
847 Characterization of ADAR2 mutants required for SG-localization. The HeLa cells co-
848 transfected with N gene and BFP-tagged ADAR2 mutants were treated with sodium
849 arsenite for 45 min to induce SGs, followed by immunostaining for N protein (red) and
850 G3BP1 (green). **c**, Time-lapse imaging of RNA-induced RBD1 phase separation.
851 Liquid droplets formed after mixing of ADAR2-RBD1 protein with 75 ng/ μ L RNA. **d**,
852 Fluorescence intensity of ADAR2-RBD1 liquid droplets forming in the presence of 75
853 ng/ μ L RNA. Data are shown as mean \pm SEM. **e**, FRAP recovery images and recovery
854 curve of ADAR2-RBD1 liquid droplets forming in the presence of RNA. The dotted
855 square displays the region of photobleaching. Data are shown as mean \pm SEM (n = 30).
856 Scale bar, 10 μ m. **f**, N protein phase separated with ADAR2-RBD1 in an RNA-
857 dependent manner. The concentration of each protein in buffer is 2 μ M. Scale bar, 10
858 μ m. **g**, Column scatter charts display the droplets area in reactions relative to Figure. 3f.
859 Data are shown as mean \pm SEM (n = 10). Statistical analysis was performed with two-
860 tailed unpaired t-test. ns > 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
861 ns, no significant.

862 **Fig. 5 N^{F17A} protein fails to penetrate into deaminases-involved RNP condensates,**
863 **which impaires deaminases-mediated viral RNA editing activity.** **a**, Schematic
864 domain structure of NF17A protein. **b**, F17A mutation in N protein impaired the N
865 protein phase separation with G3BP1. Scale bar, 10 μ m. **c**, Column scatter charts
866 display the droplets area in reactions related to panel **b**. **d**, N^{F17A} protein still possessed
867 the interaction ability with ADAR2. HeLa cells were co-transfected with plasmids
868 encoding GFP-tagged N wild type or N^{F17A} mutant and HA-tagged ADAR2. Cell

869 lysates were immunoprecipitated with an anti-GFP antibody and the bound proteins
870 were then analysed by Western blotting. **e**, N^{F17A} protein failed to penetrate into
871 deaminases-involved RNP condensates. The HeLa cells co-transfected with N wild type
872 or N^{F17A} mutant were treated with sodium arsenite for 45 min to induce SGs, followed
873 by immunostaining for N protein (green) and the endogenous ADAR2 (red). **f**, The
874 enrichment of N protein mRNA was measured by RIP assay in HeLa cells treated with
875 or without AS treatment. HeLa cells were transfected with N wild type or N^{F17A} mutant
876 with GFP tag for 48 h and then treated with or without AS treatment for 45 min. Lysates
877 were prepared and split for incubation with mouse anti-ADAR2 antibody. Co-
878 precipitated RNA was analyzed by qRT-PCR (n = 3). Data are shown as mean ± SEM.
879 **g**, N^{F17A} protein failed to penetrate into deaminases-involved RNP condensates, which
880 impaired deaminases-mediated viral RNA editing activity. Values and error bars were
881 represented as the mean ± SEM of three independent biological replicates (allelic
882 fraction ≥0.03%). **h**, Average proportion of nucleotide changes in the SARS-CoV-2
883 transcriptomes using SARS-CoV-2 N protein WT or N^{F17A}-based genetic
884 complementation system. Values and error bars were represented as the mean ± SEM
885 of three independent biological replicates. **i**, Allelic fraction of SNVs for A19736G and
886 C27970T in the SARS-CoV-2 transcriptomes using SARS-CoV-2 WT N protein or
887 N^{F17A}-based genetic complementation system. Values and error bars were represented
888 as the mean ± SEM of three independent biological replicates. Statistical analysis was
889 performed with two-tailed unpaired t-test. ns > 0.05, *P < 0.05, **P < 0.01, ***P <
890 0.001, ****P < 0.0001. ns, no significant.

891 **Fig. 6 Schematic illustration depicting how SARS-CoV-2 hijacks host deaminases**
892 **to achieve viral mutagenesis and evolution.**

893

Figures




Figure 1

SARS-CoV-2 N protein interacts with host deaminases and links deaminases to edit viral RNA. a, Average proportion of nucleotide changes in the SARS-CoV-2 transcriptomes. $n = 3$ (allelic fraction $\geq 0.1\%$). The X-axis is the original nucleotide of SARS-CoV-2 genome, and indicative colour blocks represent nucleotides

to which original nucleotide were mutated. b, Sequence contexts for A-to-I (G) and C-to-U (T) edited sites in viral transcriptome. c, Allelic fraction of SNVs identified in the SARS CoV-2 transcriptomes using SARS-CoV-2 N protein-based genetic complementation system. n = 3 (allelic fraction $\geq 0.02\%$). d, The number of SNVs identified in the SARS CoV-2 transcriptomes using SARS-CoV-2 N protein-based genetic complementation system after one and six passages (P1 and P6) (allelic fraction $\geq 0.1\%$, n = 3). Data are shown as mean \pm SEM. e, N protein interacted with host deaminases. HeLa cells were co-transfected with plasmids encoding GFP-tagged N protein and Flag control or Flag tagged host deaminases, including APOBEC1 (A1), activation-induced cytidine deaminase (AID), APOBEC2 (A2), APOBEC3 (3A-3D and 3F-3H), APOBEC4 (A4), ADAR1 (AD1) and ADAR2 (AD2). Cell lysates were immunoprecipitated with an anti Flag antibody and the bound proteins were then analysed by western blotting. f, The enrichment of N protein mRNA was measured by RIP assay in HeLa cells (n = 3). HeLa cells were transfected with N gene with GFP tag and lysates were collected 48 h after transfection. Lysates were prepared and split for incubation with mouse anti-ADAR2 antibody. Co-precipitated RNA was analyzed by qRT-PCR (n = 3). Data are shown as mean \pm SEM. g, Average proportion of nucleotide changes in the N gene in HeLa cells. Cells were transfected with the N gene and then were lysed in TRIzol reagent. The mRNA was reversely transcribed and cDNA were amplified. The amplicons were analysed by deep sequencing. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction $\geq 0.02\%$). The X-axis is the original nucleotide of N gene, and indicative colour blocks represent nucleotides to which original nucleotide were mutated. h, ADAR2 specifically interacted with SARS-CoV-2 N protein. HeLa cells were co-transfected with plasmids encoding H tagged ADAR2 and GFP control or GFP-tagged SARS-CoV-2 genes, including nsp7 (n7), nsp8 (n8), nsp9 (n9), nsp12 (n12), nsp16 (n16), spike (S), E, M and N. Cell lysates were immunoprecipitated with an anti-GFP antibody and the bound proteins were then analysed by western blotting. Statistical analysis was performed with two-tailed unpaired t-test. ns > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, no significant.




Figure 2

The condensation of N protein-deaminases complex efficiently enhances viral RNA mutagenesis. a, N protein interacted with host G3BP1 and deaminase APOBEC3G or ADAR2. HeLa cells were co-transfected with plasmids encoding GF tagged N protein or GFP control and HA-tagged APOBEC3G (A3G) or ADAR2. Cell lysates were immunoprecipitated with an anti-GFP antibody and the bound proteins were then analysed by western blotting with antibodies against HA or G3BP1. b, APOBEC3G or ADAR2 co-localized

with N protein in stress granules in HeLa cells. The HeLa cells transfected with the N gene and APOBEC3G or ADAR2 were treated with sodium arsenite (AS) for 45 min to induce SG formation, followed by immunostaining for the N protein (red), A3G or ADAR2 (blue) and endogenous G3BP1. Scale bar: 20 μm . c, The condensate formation of N protein-deaminases complex enhanced N protein interaction with A3G or ADAR2 protein. HeLa cells transfected with N gene and Flag control or Flag-tagged deaminases, including AID, A3G, A3H and ADAR2, were treated with or without AS. Cell lysates were immunoprecipitated with an anti-flag antibody and the bound proteins were then analysed by Western blotting. d, The enrichment of N protein mRNA was measured by RIP assay in HeLa cells treated with or without AS treatment. HeLa cells were transfected with N gene with GFP tag for 48 h and then treated with or without AS treatment for 45 min. Lysates were prepared and split for incubation with mouse anti-ADAR2 antibody. Co-precipitated RNA was analyzed by qRT-PCR ($n = 3$). Data are shown as mean \pm SEM. e, The formation of RNP condensation promoted the account of SNVs identified in the N gene in HeLa cells. Cells were transfected with the N gene with or without sodium arsenite (AS) for 10 h and then lysed in TRIzol reagent. The mRNA was reversely transcribed and cDNA were amplified. The amplicons were analysed by deep sequencing. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction $\geq 0.02\%$). f, The formation of RNP condensation promoted the account of SNVs identified in the spike gene in HeLa cells. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction $\geq 0.02\%$). g, The formation of RNP condensation promoted the account of SNVs identified in the Orf 8 in HeLa cells. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction $\geq 0.02\%$). h, Allelic fraction of SNVs for each nucleotide change in the N gene in HeLa cells treated with or without AS treatment ($n = 3$). Data are shown as mean \pm SEM. i, Allelic fraction of SNVs for each nucleotide change in the spike gene in HeLa cells treated with or without AS treatment ($n = 3$). Data are shown as mean \pm SEM. j, Allelic fraction of SNVs for A23403G (spike protein: D614G) in HeLa cells ($n = 3$). Data are shown as mean \pm SEM. Data were normalized to 100% by the allelic fraction of HeLa cells without AS treatment. k, Allelic fraction of SNVs for C27972T (ORF8:Q27*) in HeLa cells ($n = 3$). Data are shown as mean \pm SEM. Data were normalized to 100% by the allelic fraction of HeLa cells without AS treatment. Statistical analysis was performed with two-tailed unpaired t-test. ns > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, no significant.




Figure 3

The disruption of N protein/deaminases-involved condensates attenuates viral RNA mutagenesis. a, G3BP1/2 dKO abolished the formation of N protein/deaminases-involved condensates. b, The disruption of N protein/deaminases involved condensates attenuated ADAR-mediated RNA editing. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction \geq 0.03%). c, The disruption of N protein/deaminases-involved condensates attenuated APOBEC-mediated RNA editing. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction \geq 0.03%). d, ADAR1/2 dKO reduced ADAR-mediated RNA editing. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction \geq 0.03%). e, The RNP condensation failed to increase ADAR-mediated RNA mutagenesis due to ADAR1/2 dKO. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction \geq 0.03%). Statistical analysis was performed with two-tailed unpaired t-test. ns $>$ 0.05, * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. ns, no significant.




Figure 4

RNA binding domain is required for ADAR2 to form phase separation mediated RNP condensates with N protein. a, Characterization of ADAR2 mutants required for interaction with N protein. Top, schematic domain structure of ADAR2. HeLa cells were co-transfected with plasmids encoding N protein and Flag control or Flag-tagged host ADAR2 truncations. Cell lysates were immunoprecipitated with an anti-Flag antibody and the bound proteins were then analysed by Western blotting. b, Characterization of ADAR2

mutants required for SG-localization. The HeLa cells co transfected with N gene and BFP-tagged ADAR2 mutants were treated with sodium arsenite for 45 min to induce SGs, followed by immunostaining for N protein (red) and G3BP1 (green). c, Time-lapse imaging of RNA-induced RBD1 phase separation. Liquid droplets formed after mixing of ADAR2-RBD1 protein with 75 ng/ μ L RNA. d, Fluorescence intensity of ADAR2-RBD1 liquid droplets forming in the presence of 75 ng/ μ L RNA. Data are shown as mean \pm SEM. e, FRAP recovery images and recovery curve of ADAR2-RBD1 liquid droplets forming in the presence of RNA. The dotted square displays the region of photobleaching. Data are shown as mean \pm SEM (n = 30). Scale bar, 10 μ m. f, N protein phase separated with ADAR2-RBD1 in an RNA dependent manner. The concentration of each protein in buffer is 2 μ M. Scale bar, 10 μ m. g, Column scatter charts display the droplets area in reactions relative to Figure. 3f. Data are shown as mean \pm SEM (n = 10). Statistical analysis was performed with two tailed unpaired t-test. ns > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, no significant.





Figure 5

NF17A 862 protein fails to penetrate into deaminases-involved RNP condensates, which impairs deaminases-mediated viral RNA editing activity. a, Schematic domain structure of NF17A protein. b, F17A mutation in N protein impaired the N protein phase separation with G3BP1. Scale bar, 10 μm . c, Column scatter charts display the droplets area in reactions related to panel b. d, N F17A protein still possessed the interaction ability with ADAR2. HeLa cells were co-transfected with plasmids encoding GFP-tagged N

wild type or N F17A mutant and HA-tagged ADAR2. Cell lysates were immunoprecipitated with an anti-GFP antibody and the bound proteins were then analysed by Western blotting. e, N F17A protein failed to penetrate into deaminases-involved RNP condensates. The HeLa cells co-transfected with N wild type or N F17A mutant were treated with sodium arsenite for 45 min to induce SGs, followed by immunostaining for N protein (green) and the endogenous ADAR2 (red). f, The enrichment of N protein mRNA was measured by RIP assay in HeLa cells treated with or without AS treatment. HeLa cells were transfected with N wild type or N F17A mutant with GFP tag for 48 h and then treated with or without AS treatment for 45 min. Lysates were prepared and split for incubation with mouse anti-ADAR2 antibody. Co878 precipitated RNA was analyzed by qRT-PCR (n = 3). Data are shown as mean \pm SEM. g, N F17A protein failed to penetrate into deaminases-involved RNP condensates, which impaired deaminases-mediated viral RNA editing activity. Values and error bars were represented as the mean \pm SEM of three independent biological replicates (allelic fraction $\geq 0.03\%$). h, Average proportion of nucleotide changes in the SARS-CoV-2 transcriptomes using SARS-CoV-2 N protein WT or NF17A -based genetic complementation system. Values and error bars were represented as the mean \pm SEM of three independent biological replicates. i, Allelic fraction of SNVs for A19736G and C27970T in the SARS-CoV-2 transcriptomes using SARS-CoV-2 WT N protein or N F17A -based genetic complementation system. Values and error bars were represented as the mean \pm SEM of three independent biological replicates. Statistical analysis was performed with two-tailed unpaired t-test. ns > 0.05, *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. ns, no significant.



- 1 N protein interacts with host deaminases
- 2 Host deaminases-mediated viral RNA mutation
- 3 Degraded viral RNA due to RNA mutation
- 4 Newly formed RNA due to RNA mutation
- 5 RNP formation to enhance viral RNA mutation

Figure 6

Schematic illustration depicting how SARS-CoV-2 hijacks host deaminases to achieve viral mutagenesis and evolution.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementalinformation.pdf](#)